149 related articles for article (PubMed ID: 35596071)
1. CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease.
Knopman D; Sano M; Feldman HH
Nat Rev Neurol; 2022 Jul; 18(7):379-380. PubMed ID: 35596071
[No Abstract] [Full Text] [Related]
2. CMS Proposes Medicare Coverage Policy for Monoclonal Antibody-Based Alzheimer Treatment.
J Nucl Med; 2022 Mar; 63(3):12N. PubMed ID: 35232884
[No Abstract] [Full Text] [Related]
3. Statement from The Memory and Aging Program at Butler Hospital on CMS National Coverage Determination for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease.
R I Med J (2013); 2022 May; 105(4):75. PubMed ID: 35476744
[No Abstract] [Full Text] [Related]
4. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
5. Amyloid Hypothesis: The Emperor's New Clothes?
Høilund-Carlsen PF; Barrio JR; Werner TJ; Newberg A; Alavi A
J Alzheimers Dis; 2020; 78(4):1363-1366. PubMed ID: 33164938
[TBL] [Abstract][Full Text] [Related]
6. How donanemab data address the coverage with evidence development questions.
Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
Rabinovici GD; La Joie R
JAMA; 2023 Aug; 330(6):507-509. PubMed ID: 37459124
[No Abstract] [Full Text] [Related]
8. CMS issues new instructions on PET coverage.
J Nucl Med; 2014 Apr; 55(4):9N-10N. PubMed ID: 24692282
[No Abstract] [Full Text] [Related]
9. Alzheimer disease: Lessons from immunotherapy for Alzheimer disease.
Wang YJ
Nat Rev Neurol; 2014 Apr; 10(4):188-9. PubMed ID: 24638135
[No Abstract] [Full Text] [Related]
10. Medicare Coverage of Aducanumab - Implications for State Budgets.
Sachs RE; Bagley N
N Engl J Med; 2021 Nov; 385(22):2019-2021. PubMed ID: 34797617
[No Abstract] [Full Text] [Related]
11. Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-β-Amyloid Monoclonal Antibody Treatment.
Bonomi S; Samara A; Balestra N; Padalia A; Benzinger TL; Kang P
Neurology; 2023 Dec; 101(23):1079-1080. PubMed ID: 37816643
[No Abstract] [Full Text] [Related]
12. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
van Dyck CH
Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo A; Lopera F
Colomb Med (Cali); 2016 Dec; 47(4):203-212. PubMed ID: 28293044
[TBL] [Abstract][Full Text] [Related]
14. [Advances in anti-beta antibody treatment of Alzheimer's disease].
Zhang JH; Liang P
Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):633-5. PubMed ID: 18070457
[No Abstract] [Full Text] [Related]
15. [Amyloid-beta protein vaccine therapy for alzheimer's disease].
Hara H
Nihon Naika Gakkai Zasshi; 2006 Jun; 95(6):1122-8. PubMed ID: 16846064
[No Abstract] [Full Text] [Related]
16. [Current status of Alzheimer's disease immunotherapy and pharmacologic effect of BAN2401.].
Araki S
Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):21-5. PubMed ID: 20628209
[No Abstract] [Full Text] [Related]
17. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
[TBL] [Abstract][Full Text] [Related]
18. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
[TBL] [Abstract][Full Text] [Related]
19. Vaccines: chasing the dream.
Schnabel J
Nature; 2011 Jul; 475(7355):S18-9. PubMed ID: 21760578
[No Abstract] [Full Text] [Related]
20. Genentech's Alzheimer's antibody trial to study disease prevention.
Garber K
Nat Biotechnol; 2012 Aug; 30(8):731-2. PubMed ID: 22871696
[No Abstract] [Full Text] [Related]
[Next] [New Search]
